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ARTICLE 
 
RNAi-based glyconanoparticles trigger apoptotic 
pathways for in vitro and in vivo enhanced cancer-cell 
killing 
João Condea,†, Furong Tianb,†, Yulan Hernandezc, Chenchen Baod, Pedro V. Baptistae, 
Daxiang Cuid, Tobias Stoegerb* and Jesus M de la Fuentec,d,f* 
Gold glyconanoparticles (GlycoNPs) are full of promises in areas like biomedicine, 
biotechnology and material science due to their amazing physical, chemical and biological 
properties. Here, siRNA GlycoNPs (AuNP@PEG@Glucose@siRNA) in comparison to 
PEGylated GlycoNPs (AuNP@PEG@Glucose) were applied in vitro to a luciferase-
CMT/167 adenocarcinoma cancer cell line and in vivo via intratracheal instillation 
directly into the lung of B6 albino mice grafted with luciferase-CMT/167 adenocarcinoma 
cells. siRNA GlycoNPs but not PEGylated GlycoNPs induced the expression of pro-
apoptotic proteins such as Fas/CD95 and caspases 3 and 9 in CMT/167 adenocarcinoma 
cells in a dose dependent manner, independent from the inflammatory response, 
evaluated by bronchoalveolar lavage cell counting. Moreover,  in vivo pulmonary 
delivered siRNA GlycoNPs were capable of targeting c-Myc gene expression (a crucial 
regulator of cell proliferation and apoptosis) via in vivo RNAi in tumour tissue, leading to 
a ~80% reduction in tumour size without inflammation associated.   
 
Introduction 
Carbohydrates are, together with nucleic acids and proteins, 
important molecules for life. Although individual carbohydrate 
interactions are relatively weak, nature utilized multivalent 
interactions between these cell surface ligands and their 
respective biological receptors to modulate biological events 
such as the ones related to cell adhesion, normal tissue growth 
and repair, viral/bacterial infection, signal transduction, 
trapping of leukocytes, and gene transfer. So the decoding of 
carbohydrate interactions opens up the possibility to employ 
physiologically inert gold nanoclusters in diagnostics and/or 
therapy.1 Among them, gold glyconanoparticles (GlycoNPs) 
have drawn more attention owing to their well-defined 
features as water-soluble carbohydrate-functionalized 
nanoclusters with a promising potential for chemical 
glycobiology, biomedicine, diagnostics and clinical 
applications. In the last 10 years, de la Fuente and co-workers 
have extensively reported a pioneered integrated 
glyconanotechnology strategy based on the use of 
nanoparticles to study and evaluate carbohydrate–
carbohydrate, carbohydrate–protein interactions 2-6 and used 
as potential tools in anti-adhesive therapy 7, for cell-cell 
adhesion studies 8 and for the prevention of pathogen 
invasion.9 
Small carbohydrates such as glucose can be attached to gold 
nanoparticles (AuNPs) and may be useful mainly in sensitive 
colorimetric assays.10 However, to the best of our knowledge 
the use of siRNA GlycoNPs for the regulation of important 
genes of the apoptotic pathways has never been described so 
far. 
Herein, a novel structure of multifunctional RNAi-based 
GlycoNPs functionalized with glucose, poly(ethylene glycol) 
(PEG), a biotin linked fluorophore and cMyc targeting siRNA 
were designed to trigger apoptosis and gene silencing 
pathways (see Figure 1). Via a chemical approach, the 
functional properties and moieties of this kind of 
multifunctional nanostructure can be easily tuned and 
quantified as recently reported by our group.11,12 In fact, we 
have provided evidence of in vitro and in vivo efficient RNAi via 
the synthesis of a library of novel multifunctional AuNPs, 
tested in three biological systems of increasing complexity: in 
vitro cultured human cells (HeLa cells), in vivo freshwater polyp 
(Hydra vulgaris), and in vivo mice models (B6 albino mice).11,13  
In view of the great number of studies concerning glucotoxicity 
attributed to the inability of cells to reduce glucose uptake 
when exposed to chronic hyperglycemia, we designed novel 
siRNA GlycoNPs that predispose gene expression to apoptosis 
via enhancement of cell death receptors. In fact, it is known 
that high levels of glucose induces apoptosis via upregulation 
of cell death receptors – Fas – providing a link between type 1 
and type 2 diabetes.14,15 Hyperglycemia is the central initiating 
factor for all types of diabetic microvascular disease. Studies in 
endothelial cell cultures clearly show glucose toxicity by 
delaying replication, disturbing cell cycle, increasing DNA 
damage and accelerating cell death.16,17  
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Fi
gure 1. (A) Multifunctional siRNA Glyconanoparticles (siRNA GlycoNPs) trigger apoptotic pathways (B) with expression of cell 
death receptors (Fas) and caspases. The death domain-containing receptor Fas can sense an external signal and activate the 
apoptosis pathway through the Fas-related death domain. This pathway is mediated by the activation of caspase-8, followed by 
direct cleavage of downstream effector caspases. The apoptosis pathway can also be initiated cytoplasmatic, through activation of 
intracellular changes resulting in the release of proapoptotic factors from the mitochondria. The release of these factors leads to the 
activation of caspase-9, and ultimately results in the activation of effector caspases (e.g. caspase 3) and consequently to cell death 
by apoptosis. (C) The siRNA glycoNPs have also the capacity to trigger gene silencing via activation of the RNA interference 
pathway, by double-stranded RNA (i.e. siRNA), promoting nucleolytic degradation of the target mRNA and/or translational 
suppression. 
 
Maedler et al. also reported that increased glucose 
concentration by itself induces apoptosis in human pancreatic 
β-cells via the upregulation of Fas receptors, which can interact 
with the constitutively expressed FasL (Fas ligand) on 
neighbouring β-cells. Fas-FasL interaction leads to cleavage of 
procaspase-8 to caspase-8, which promotes caspase-3 
activation.14 The stimulation of death receptors such as Fas 
(APO-1/CD95) and creation of DISC (death-inducing signalling 
complex) are commonly referred as the starting point in the 
extrinsic apoptosis execution phase; whereas caspase-9 
activation is a downstream marker for mitochondrial 
membrane permeabilisation, in the intrinsic apoptotic 
pathway.18 Both pathways converge on the same terminal 
outcome, which is initiated by the cleavage of caspase-3 and 
results in DNA fragmentation, degradation of cytoskeletal and 
nuclear proteins, formation of apoptotic bodies, expression of 
ligands for phagocytic cell receptors and finally clearance by 
phagocytic cells. 
Herein, the in vitro and in vivo activation of apoptotic and gene 
silencing pathways via RNAi GlycoNPs will be dissected and the 
clinical outcome in terms of lung cancer progression 
evaluated.  
 
 
Results and discussion 
Glyconanoparticles synthesis and characterization 
Nanoscale ARTICLE 
  
Multifunctional gold glyconanoparticles were prepared by reduction 
of sodium tetracholoroaurate(III) hydrate with sodium citrate as 
described by Turkevich and Frens 19,20, and stabilized with 
polyethyleneglycol (PEG) and subsequent conjugation with 
glucose, biotin and siRNA. Briefly, the obtained AuNPs, with 
an average diameter of 14 nm, were subsequently 
functionalized with two types of thiolated poly(ethylene glycol) 
(PEG) – a commercial carboxylated PEG (HS-EG(8)-(CH2)2-
COOH) and another one synthesized in our lab with an azide 
group at the end (HS-(CH2)3-CONH-EG(6)-(CH2)2-N3) - by 
exchange of the citrate groups,. For the subsequent attachment 
of thiolated siRNA using the covalent approach previously 
described 11, the AuNPs were functionalized with a 40% degree 
of coverage of the surface using 50% of each PEG chain.  
Once obtained stable and biocompatible PEGylated AuNPs we 
functionalized them with amine-modified biotin and glucose 
through an EDC coupling reaction forming amide bonds with 
the carboxylic groups exposed on the surface. The covalent 
conjugation of the biotin was evaluated by the crosslinking 
induced by the effective attachment of streptavidin to up to four 
biotin molecules and also determined by indirect quantification 
by the Bradford assay. Concerning the attachment of glucose, 
the change of the net charge and the aggregation of the AuNPs 
effectively functionalized in the presence of the lectin 
Concanavalin A 21 were used to confirm the conjugation, again 
via the occurrence of crosslinking induced due to the multi-
interaction between glucose and Con A. Lastly, GlycoNPs were 
functionalized with thiolated anti cMyc siRNA through direct 
attach of the thiol group to the gold core of the AuNP by 
establishing strong pseudo-covalent bonds Au-S (for further 
details see Supplementary Information) 
 
Triggering apoptotic pathways via glyconanoparticles 
The functionalized nanoparticles were administered in vitro to 
a luciferase-CMT/167 adenocarcinoma cancer cell line and in 
vivo via instillation directly into the lung of cancer mice (B6 
albino mice, induced with luciferase-CMT/167 
adenocarcinoma cells). 48 hours upon treatment with 
increasing concentrations (10, 100 and 200 µg/mL) of 
PEGylated GlycoNPs (AuNP@PEG@Glucose) and siRNA 
GlycoNPs (AuNP@PEG@Glucose@siRNA) cells were assessed 
for the expression of proapoptotic genes such as Fas/CD95 and 
caspases-3 and -9, as well as the siRNA target c-Myc gene, that 
also triggers apoptosis in association with tumour suppressors 
such as ARF and p53.22 
Representative confocal images of LA-4 adenocarcinoma-
loaded cells show that siRNA GlycoNPs accomplish high cellular 
uptake (3-fold) and trigger apoptosis by enhancing the 
expression of Fas death receptor, as detected by a significant 
increase (2-fold) of Fas/CD95 fluorescence (Figure 2A).  
Glucose-surface functionalization has also been developed for 
siRNA GlycoNPs as a metabolic transporter to enhance the 
uptake of the therapeutic nanoparticles by cancer cells. In fact, 
tumour cells display a high rate of glucose uptake and 
glycolysis, since cell proliferation requires increased uptake of 
nutrients (e.g. glucose and glutamine). Cancer cells exhibit a 
high rate of glycolysis even in the presence of oxygen (aerobic 
glycolysis). The major function of aerobic glycolysis is to 
maintain high levels of glycolytic intermediates to support 
anabolic reactions in cells. This explains increased glucose 
metabolism in proliferating cells.18 In addition to cell 
proliferation, increased glucose uptake may also be associated 
with mitochondria damage in cancer cells, or an adaptation to 
hypoxia environments within tumours or to mitochondria 
shutdown by cancer genes (eg. c-Myc) involved in the cell's 
apoptosis program.24 In fact, high glucose levels proved to be 
pro-apoptotic, increasing the sensitivity to apoptosis via Fas 
activation.14 
Our results suggest that siRNA GlycoNPs activate apoptotic 
pathways by regulating cell death receptors and effective 
caspases, and the effect is dose dependent. Increasing 
concentrations (10, 100 and 200 µg/mL) of siRNA GlycoNPs 
show enhancement in Fas expression in a dose dependent 
manner, as it can be seen by increase of Fas/CD95 
fluorescence (see Figure 2B) in a 1.5-fold from 10 to 100 
µg/mL and in a 3-fold from 100 to 200 µg/mL of NPs. 
In order to corroborate these data and evaluate siRNA 
GlycoNPs’ involvement in the activation of crucial proapoptotic 
proteins, expression of Fas, caspase-3 and caspase-9 was 
assessed by Western blot in luciferase-CMT/167 
adenocarcinoma cancer cell line. The expression of Fas, 
activated/cleaved caspase-3 and caspase-9 proteins was 
significantly higher (5 fold) for siRNA GlycoNPs at 10, 100 and 
200 µg/mL compared to PEGylated GlycoNPs (Figure 3A). 
The expression of Fas and caspases-3 from cell treated with 10 
µg/mL of siRNA GlycoNPs indicates the strong activation of 
both intrinsic and extrinsic apoptotic pathways. Enhanced 
activation of caspase-9 by siRNA GlycoNPs can especially be 
observed at 200 µg/mL (see Figure 2), which in turn may 
induce the activation of procaspase-3, which leads to the 
apoptosome formation.25 Once formed, the apoptosome can 
then recruit and activate the inactive pro-caspase-9, which can 
activate effector caspases and trigger a cascade of events 
leading to apoptosis. Finally, after the activation of caspase-9, 
the effector caspase-3 is activated and marks the endpoint of 
apoptosis.25 
 
 
Figure 2. Gold siRNA glyconanoparticles trigger apoptotic 
pathways via expression of the Fas cell death receptor. (A) 
Immunostaining of Fas/CD95 in luciferase-CMT/167 
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adenocarcinoma cells treated with 200 µg/mL of PEGylated 
glycoNPs and siRNA GlycoNPs for 48 hours. Cells stained for 
DAPI (nuclei) in blue, actin (phalloidin) in green, Fas/CD95 
stained in red and NPs (conjugated streptavidin with Cy7-
Allophycocyanin bound with biotin) in white (Scale bars, 20 
μm). (B) Immunostaining of Fas/CD95 in luciferase-CMT/167 
adenocarcinoma cells treated with 10, 100 and 200 µg/mL of 
siRNA GlycoNPs. Cells stained for Fas/CD95 stained in red and 
NPs (conjugated streptavidin with Cy7-Allophycocyanin bound 
with biotin) in green (Scale bars, 20 μm). The results shown are 
representative for at least three independent experiments. 
 
 
This finding further supports the notion that siRNA GlycoNPs 
promote apoptosis within the LA-4 adenocarcinoma cancer cell 
line when exposed for 48 hours at a concentration of 100 and 
200 µg/ml (Figure 3A,C). PEGylated GlycoNPs showed no 
changes in expression of the assessed cell death receptor or 
caspases (Figure 3A,C).  
RNAi-based GlycoNPs were also functionalized with a siRNA to 
mediate silencing of c-Myc gene expression. c-Myc is widely 
known as a crucial regulator of cell proliferation in normal and 
neoplastic cells, and recent reports strongly support a dual 
function model for c-Myc as a co-ordinate activator of cell 
proliferation and apoptosis.28 Several studies provide 
evidences that c-Myc function is closely related to apoptosis 
and that the induction or inhibition of apoptosis by this protein 
may depend on the level of expression or cell lineages used.28-
30 To assess whether anti-cMyc siRNA GlycoNPs attenuate MYC 
protein synthesis, its expression was also evaluated by western 
blot in luciferase-CMT/167 adenocarcinoma cancer cell line 
(Figure 3B,C) after exposure to PEGylated GlycoNPs and siRNA 
GlycoNPs. Western blot results clearly show that c-Myc 
donwregulation (14-fold) is attained with only 10 µg/mL of 
siRNA GlycoNPs (Figure 3B,C). PEGylated GlycoNPs show no 
silencing effect for all NPs concentration (Figure 3B,C). 
 
 
Figure 3. Activation of apoptotic pathway via siRNA GlycoNPs. 
Fas, Caspase 3, Caspase 9 (A) and c-Myc expression (B) in 
Western blot after LA-4 adenocarcinoma cancer cells treated 
with increasing concentrations (0.1, 1, 10, 100 and 200 µg/mL) 
of PEGylated GlycoNPs and siRNA GlycoNPs. (C) Comparative 
graph with the expression of Fas, and activated Caspases 3 and 
9 and c-Myc after LA-4 adenocarcinoma cancer cells treated 
with PEGylated GlycoNPs and siRNA GlycoNPs. The results 
shown are representative for at least three independent 
experiments. 
 
 
In vivo RNAi triggering via siRNA glyconanoparticles 
For in vivo evaluation of GlycoNPs treatment on c-Myc 
expression in a mouse lung tumour model, 200 µg/mL of 
PEGylated GlycoNPs and siRNA GlycoNPs were administered to 
mice previously induced with luciferase-CMT/167 
adenocarcinoma cells. Four weeks after orthotropic lung 
cancer induction mice were treated by instillation of 0.3 pmol 
AuNP (at weeks 12, 13, 14 and 15), respectively, in 50 μl 
pyrogene-free distilled water, followed by 100 μl of air. Figure 
4A shows Hematoxylin and Eosin staining (H&E) and 
immunolocalisation of c-Myc expression in mice lung tissues 
for Sham, PEGylated GlycoNPs and siRNA GlycoNPs groups. 
PEGylated GlycoNPs treated group demonstrates a cancer lung 
tissue characterized by hypercellularity and thickened alveolar 
septa. Cancer cell have spread throughout the lung tissue, and 
large areas of deformed lung structures can be observed 
(Figure 4A). Severe interstitial inflammatory cell infiltration is 
noted in the PEGylated GlycoNPs treated group, with 
predominance of perivascular and peribronchiolar edemas 
(Figure 4A arrows). In the siRNA GlycoNPs-treated group in 
contrast a significant decrease in the incidence and severity of 
tumour foci in lung can be observed, revealing the potency of 
siRNA GlycoNPs in reducing the tumour mass in the lung 
cancer mouse model. Only few, scattered cancer cells can get 
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localized with recovered alveolar lung tissue. Concerning 
confocal images of lung tissue, Figure 4B shows high 
expression of MYC protein in cytoplasm of tumour cells after 
exposure to PEGylated GlycoNPs. Whereas, Figure 4C illustrate 
tumour cells treated with siRNA GlycoNPs and shows 
downregulation of local MYC expression (6-fold), probably 
leading tumour cells to apoptosis, and consequently inhibiting 
cell proliferation. Moreover, cancer cells in lung tissue 
accumulate more siRNA GlycoNPs (2-fold) (Figure 4C) than 
PEGylated GlycoNPs (Figure 4B). Xing and co-workers also 
reported that glucose and antisense oligodeoxynucleotides-
capped AuNPs showed significantly increased cellular uptake 
compared to neutral nanoparticles in breast cancer 30 and 
prostate cancer cells.31 
 
 
Figure 4. RNAi triggering in mice. (A) Hematoxylin and eosin 
(H&E) stains of Sham (healthy mice without lung cancer 
induction of luciferase-CMT/167 adenocarcinoma cells), 
PEGylated GlycoNPs and siRNA GlycoNPs treated groups in 
lung tissue with induction of LA-4 adenocarcinoma cells. 
Severe interstitial inflammatory cell infiltration is noted, with 
predominance of perivascular and peribronchiolar edemas 
(arrows) in PEGylated GlycoNPs only. Immunohistochemical 
images of lung tissue of PEGylated GlycoNPs (B) and siRNA 
GlycoNPs (C) treated groups. Cells in lung tissue stained for 
actin in green and MYC stained in red (Scale bars, 100 μm). 
 
 
Inflammatory response and in vivo glyconanoparticles 
biodistribution in mice 
The inflammatory response of the assembled glyco-
nanoconjugates was evaluated by bronchoalveolar lavage 
(BAL) cell analysis. At steady state conditions, the most 
abundant cells retrieved in BAL fluid are the resident alveolar 
macrophages that line the alveolar space,  (about 98% of BAL 
cells), and under inflammatory conditions infiltrating 
leukocytes such as lymphocytes and neutrophils. 
Consequently, evaluation of the number of BAL macrophages, 
lymphocytes and neutrophils was used to characterize the 
inflammatory response (Figure 5) upon treatment with 
PEGylated GlycoNPs and siRNA GlycoNPs in cancer mice during 
1, 3 and 14 days. Figure 5A shows representative microscope 
images of BAL cells at day 1 and 14 for 200 µg/mL of PEGylated 
GlycoNPs and siRNA GlycoNPs. Figure 5B shows evaluation of 
the number of macrophages, lymphocytes and neutrophils in 
cancer mice during 1, 3 and 14 days after PEGylated GlycoNPs 
and siRNA GlycoNPs instillation. No multinucleated 
macrophages, indicators of a foreign body response are found 
at any condition. As expected13, Sham treated group (healthy 
mice without lung cancer induction of luciferase-CMT/167 
adenocarcinoma cells) reveals intact and normal alveolar 
macrophages (Figure 5A). Inflammatory cells infiltration is 
noted by increasing numbers of neutrophils in the siRNA 
GlycoNPs (200 µg/mL) treated groups on days 1 and 14 (Figure 
5A). PEGylated and siRNA GlycoNPs show the same pattern 
and number of macrophages as well as neutrophils and 
lymphocytes (Figure 5B). The increased number of neutrophils 
with 200 µg/mL of PEGylated and siRNA GlycoNPs on day 1 
indicates a moderate acute and over time rapidly declining 
inflammatory response, resulting in baseline levels (sham) and 
thus negligible neutrophil numbers at day 3  and 14 after 
treatment (Figure 5B). No significant changes have been 
observed for BAL lymphocyte numbers over the period of 
investigation, pointing to the generally described innate, acute 
inflammatory response to pulmonary deposited materials 32,33 
No significant changes in the number of macrophages and 
neutrophils between PEGylated GlycoNPs and siRNA GlycoNPs 
are observed (Figure 5B). 
 
 
Figure 5. Inflammatory response in bronchoalveolar lavage 
(BAL) cells in mice during 1, 3 and 14 days of exposure to gold 
GlycoNPs. (A) Representative microscope images of BAL cells 
(scale bars, 20 μm) at days 1 and 14 for 200 µg/mL of 
PEGylated GlycoNPs and siRNA GlycoNPs. Black arrows 
indicate neutrophils. (B) Evaluation of the number of 
macrophages, lymphocytes and neutrophils was used to detect 
inflammatory response in the lungs during 1, 3 and 14 days 
after PEGylated GlycoNPs and siRNA GlycoNPs instillation. 
Sham groups correspond to healthy mice without lung cancer 
induction and any nanoparticle treatment. Error bars indicate 
± s.d, of n=6 mice. 
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In order to analyse tumour size, nanoparticle uptake and 
biodistribution in the whole body mice but predominantly in 
lung tumour tissue, tomography bioluminescence imaging was 
carried out in the mouse cancer model (B6 albino female mice 
injected with luciferase-CMT/167 adenocarcinoma cells) 
treated with 200 µg/mL of PEGylated GlycoNPs and siRNA 
GlycoNPs (Figure 6). Representative whole body images of the 
individual mice from each treated group (n = 8 animals) shown 
at fixed photon flux scale illustrates the luciferase activity 
(Figure 6A). Detection of epi-fluorescence (Figure 6B) further 
allowed localization of nanoparticle conjugated to streptavidin 
with Cy7-Allophycocyanin (Cy7APC, BD Pharmingen™) with an 
excitation wavelength of at 642 nm. Figures 6C and 6D shows 
excised organs to evaluate lung tumour size via the 
luminescence of luciferase and Figures 6E and 6F shows 
nanoparticle distribution in mice organs via the measurement 
of epi-fluorescence of nanoparticles conjugated to streptavidin 
with Cy7-Allophycocyanin (Exc = 642 nm). 
 
Figure 6. GlycoNPs uptake, whole body biodistribution and 
tumour size assessment in mice. Tomography imaging of B6 
albino female mice injected with luciferase-CMT/167 
adenocarcinoma cells (n = 8 animals per treated group) treated 
with 200 µg/mL of PEGylated GlycoNPs and siRNA GlycoNPs. 
Representative imaging of individual mice from each 
treatment group (n = 8 animals) is shown, with the same scale 
of photon flux indicating luciferase activity (A) and epi-
fluorescence (B) indicating nanoparticles conjugated to 
streptavidin with Cy7-Allophycocyanin (Cy7APC, BD 
Pharmingen™) with an excitation wavelength of at 642 nm. 
(A,B) Luminescence and epi-fluorescence images of lung 
cancer mice treated with 200 µg/mL of PEGylated GlycoNPs 
and siRNA GlycoNPs. Excised organs to evaluate lung tumour 
size via the luminescence of luciferase in mice treated with 
PEGylated AuNPs (C) and gold GlycoNPs (D). Nanoparticle 
distribution indifferent organs treated with PEGylated 
GlycoNPs (E) and siRNA GlycoNPs (F), via the measurement of 
epi-fluorescence of nanoparticles conjugated to streptavidin 
with Cy7-Allophycocyanin. 
 
 
The tomography images clearly depict that siRNA GlycoNPs 
archive an increased targeting toward lung cancer cells when 
compared to PEGylated GlycoNPs treatment, which shows no 
signal-accumulation in the respective lung tissue, for the same 
scale of epi-fluorescence. Once the lung is characterized by 
high expression of c-Myc, siRNA anti-cMyc targeting GlycoNPs 
seem to accumulate in the tissue more effectively and for a 
longer period of time than observed for PEGylated GlycoNPs 
only. Moreover, treatment of the murine lung cancer model 
with GlycoNPs leads to successful tumour size reduction 
(~80%) as depicted by the decrease in reporter luminescence 
signal (Figure 6A,C), when compared to the PEGylated 
GlycoNPs. 
 
Experimental 
Synthesis of PEGylated and siRNA GlycoNPs 
Full description of synthesis and characterization methods of 
PEGylated GlycoNPs and siRNA GlycoNPs can be found in 
Supplementary Information. 
 
Immunostaining of luciferase-CMT/167 
adenocarcinoma cells 
Cells were fixed with -20°C methanol for 10 min and with -20°C 
acetone for min on cover slips. The cover slips were washed 
twice in PBS, and then blocked with PBS containing 0.1% BSA 
for 10 min at room temperature followed by draining. The cell-
side-up of glass slide was incubated with anti-rabbit Fas (Santa 
Cruz Biotechnology) in PBS containing 1% BSA for 60 min, and 
was washed three times in PBS. The samples were incubated 
with Alexa 546 anti-rabbit or FITC 488 anti-rabbit as the 
secondary antibody and phalloidin (Invitrogen), at the 
recommended dilution, in PBS containing 1% BSA, for 30 min, 
and then was washed for three times in PBS. After DAPI 
staining, one drop of aqueous mounting medium was added 
on the cover slip and inverted carefully on a glass slide. The 
images were acquired in a Zeiss confocal microscope and the 
fluorescent density per cell was analysed by ImageJ. 
 
Western blot of Fas/CD95, caspase 3 and 9 expression 
Protein extract was boiled in sample buffer for 3 min and 
loaded onto 12% SDS-polyacrylamide gels. Details of the 
Western immunoblotting procedure have been described 
elsewhere.34 The antibodies used in this experiment were as 
follows: anti-rabbit Fas (Santa Cruz Biotechnology, 1:500 
dilution), anti-rabbit Caspase3 (cleaved) (Invitrogen, 1:500 
dilution), and anti-rabbit polyclonal Caspase9 (cleaved) 
(Abcam, 1:1000 dilution), anti-rabbit IgG horseradish 
peroxidase (Amersham-Pharmacia Biotech, 50000:1 dilution). 
The blot was visualized with an ECL kit (Amersham-Pharmacia 
Biotech).  
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In vivo targeting of PEGylated glycoNP and siRNA 
GlycoNPs 
Prior to glycoNP instillation, B6 albino mice (B6N-Tyrc/BrdCrCrl, 
Charles River, France, induced with luciferase-CMT/167 
adenocarcinoma cells) were anesthetized by intraperitoneal 
injection of a mixture of Medetomidin (0.5 mg/kg body mass), 
Midazolam (5.0 mg/kg body mass) and Fentanyl (0.05 mg/kg 
body mass). The animals were then intubated by a nonsurgical 
technique. Using a cannula inserted 10 mm into the trachea, a 
suspension containing 1×105 cancer cells or 200 µg/mL of 
PEGylated GlycoNPs and siRNA GlycoNPs, in 50 μl pyrogene-
free distilled water was instilled, followed by 100 μl air. After 
instillation animals were antagonized by subcutaneous injection 
of a mixture of Atipamezol (2.5 mg/kg body mass), Flumazenil 
(0.5 mg/kg body mass) and Naloxon (1.2 mg/kg body mass) for 
antagonization and to control awakening of the mice. Animal 
experiments were carried out according to the German law of 
protection of animal life and were approved by an external 
review committee for laboratory animal care (animal approval 
number: 55.2-1-54-2532-20-11). After 72 hours mice lungs 
were dissected and prepared for Hematoxylin and Eosin 
staining (H&E) and for immunolocalisation by a standard 
immunohistochemical procedure, to verify c-Myc expression 
and the distribution of NPs by tissue sections. 
 
Molecular analyses of MYC expression in mice 
The lung cancer tissues (from B6 albino mice induced with 
luciferase-CMT/167 adenocarcinoma cells) were embedded 
and sliced into 3 m section. A standard Hematoxylin and 
Eosin (H&E) staining was employed for cancer cells 
morphology observation. For immunolocalisation, standard 
immunohistochemical staining methods were employed: the 
tissue slide was incubated with anti-mouse c-Myc and anti-
rabbit caspase-3, (1:1000) in PBS containing 1% BSA for 60 
min, and was washed three times in Tris-buffered saline (TBS). 
The slide was incubated with 560 nm anti mouse and FITC anti-
rabbit as the secondary antibody, at the recommended 
dilution, in TBS containing 1% BSA, for 30 min, and then was 
washed for three times in PBS. The slides were mounted with 
50 µl of mounting medium. The images were acquired by a 
Zeiss confocal microscopy and the fluorescent density per cell 
analysed by ImageJ.  
 
Preparation of BAL cells/fluid for evaluation of 
inflammatory response 
BAL (bronchoalveolar lavage cells) fluid was obtained by 
injecting 4 times and recovering of two 0.5 mL aliquots of PBS 
via a tracheal cannula. Cells recovered with the lavage fluid 
(lymphocytes and neutrophils accompanying the predominant 
population of alveolar macrophages) were determined utilizing 
light microscopic cell differentiation, counting 200 cells per 
cytospin preparation. Details of the bronchoalveolar lavage 
procedure were described elsewhere.35 Mice were exposed to 
200 µg/mL of PEGylated GlycoNPs or siRNA GlycoNPs.  
 
In vivo bioluminescence imaging 
Stable clones of CMT64/61 cells, originally derived from a 
spontaneous lung adenocarcinoma of a C57Bl/ICRF mouse 32 
were generated by transfection with pGL3-Control vector 
(Promega GmbH), and co-transfection for selection with a 
linear Hygromycin resistance marker (Clonetech). A stable 
clone (CMT/167-luc) expressing high levels of firefly luciferase, 
constitutively driven by the SV40 promoter and enhancer, was 
instilled into female C57BL/6 albino mice. Prior to instillation, 
mice were anesthetized by intraperitoneal injection of a 
mixture of Medetomidin (0.5 mg/kg body mass), Midazolam 
(5.0 mg/kg body mass) and Fentanyl (0.05 mg/kg body mass). 
The animals were then intubated by a nonsurgical technique. 
Using a cannula inserted 10 mm into the trachea, a suspension 
containing 1×105 CMT/167-luc cells in 50 μl pyrogene-free 
distilled water was instilled, followed by 100 μl of air, at week 
8. Four weeks after orthotropic lung cancer induction mice 
were treated by instillation of 0.3 pmol AuNP (at weeks 12, 13, 
14 and 15), respectively, in 50 μl pyrogene-free distilled water, 
followed by 100 μl of air. After instillation animals were 
antagonized by subcutaneous injection of a mixture of 
Atipamezol (2.5 mg/kg body mass), Flumazenil (0.5 mg/kg 
body mass) and Naloxon (1.2 mg/kg body mass). Luciferase 
expression was monitored applying the IVIS® imaging system 
(Lumina, PerkinElmer) from mice bearing tumours from 
luciferase-CMT/167 cells (n = 8 animals per treated group). 
Conclusions 
Several studies were published in the last years reporting that 
some engineered gold nanoparticles induce apoptosis in cells 
via caspase pathways. Herein, we present for the first time a 
new and smart RNAi-based gold glyconanoparticle system 
capable of inducing apoptosis via hyperactivation of cell death 
receptors and caspase pathways.  In summary, we 
demonstrate that siRNA GlycoNPs have remarkable potential 
to trigger apoptosis via the enhancement of cell death 
receptors and activation of caspases. Moreover, our results 
confirm that sham, PEGylated GlycoNPs and siRNA GlycoNPs 
treated groups’ causes the same inflammatory response, 
proving that siRNA GlycoNPs trigger apoptotic pathways via 
expression of cell death receptors and effective caspases in a 
specific way, independent from the inflammatory response. 
Consequently, the switch on of the apoptotic pathways is not 
caused by any toxic and/or adverse side effects of the 
exposure to the NPs in mice. Most importantly, pulmonary 
delivered of siRNA GlycoNPs leads to a ~80% reduction in 
tumour size via in vivo RNAi in tumour tissue by targeting c-
Myc gene expression. 
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